WO2017188790A1 - Procédé de mise en prolifération et de culture de cellules immunitaires dans des conditions hypoxiques - Google Patents
Procédé de mise en prolifération et de culture de cellules immunitaires dans des conditions hypoxiques Download PDFInfo
- Publication number
- WO2017188790A1 WO2017188790A1 PCT/KR2017/004595 KR2017004595W WO2017188790A1 WO 2017188790 A1 WO2017188790 A1 WO 2017188790A1 KR 2017004595 W KR2017004595 W KR 2017004595W WO 2017188790 A1 WO2017188790 A1 WO 2017188790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- conditions
- peripheral blood
- cancer
- expression
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 43
- 230000001146 hypoxic effect Effects 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 10
- 210000002865 immune cell Anatomy 0.000 title abstract description 12
- 238000012258 culturing Methods 0.000 title abstract description 9
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 104
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 33
- 230000005880 cancer cell killing Effects 0.000 claims abstract description 33
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- 108090000695 Cytokines Proteins 0.000 claims abstract description 7
- 102000004127 Cytokines Human genes 0.000 claims abstract description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 86
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 77
- 239000001301 oxygen Substances 0.000 claims description 77
- 210000005259 peripheral blood Anatomy 0.000 claims description 22
- 239000011886 peripheral blood Substances 0.000 claims description 22
- 210000001616 monocyte Anatomy 0.000 claims description 20
- 230000036961 partial effect Effects 0.000 claims description 15
- 230000035755 proliferation Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 7
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 7
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 7
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 102000001398 Granzyme Human genes 0.000 claims description 6
- 108060005986 Granzyme Proteins 0.000 claims description 6
- 102100037850 Interferon gamma Human genes 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 6
- 229930192851 perforin Natural products 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 102000004503 Perforin Human genes 0.000 claims description 5
- 108010056995 Perforin Proteins 0.000 claims description 5
- 238000012136 culture method Methods 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 12
- 230000032683 aging Effects 0.000 description 7
- 230000030833 cell death Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 244000130402 Waltheria indica Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Definitions
- the present invention relates to a method for proliferating and culturing immune cells using hypoxic conditions that allow peripheral blood mononuclear cell-derived NK cells to be cultured under normal oxygen conditions and further cultured under hypoxic conditions to improve cancer cell killing ability and to survive in the body for a long time. .
- NK cells are one of the innate immune cells, which are capable of killing various types of cancer cells and recognize cancer cells regardless of the presence or absence of antigens.
- the immune cells injected due to the immune evasion mechanism that occurs in the large tumor tissues cause deactivation, and the cancer cell attack ability is lost.
- the major cause of this immune evasion mechanism is that the interior of the tumor is a hypoxic environment and this environment is a problem in the treatment of solid cancer patients by providing a condition that NK cells can not effectively kill cancer cells.
- hypoxic oxygen partial pressures of 3% (peripheral tissue) to 14% (lung) depending on tissue, and lower oxygen levels are referred to as hypoxic, often 0.5% to 3%. It has been reported that tumor cells maintain and promote growth under hypoxic conditions, whereas normal cells and immune cells do not grow well under hypoxia. In addition, in the case of immune cells, hypoxic conditions are known to inhibit the function of immune cells. In NK cells, NKp30, NKp44, NKp46, and NKG2D, which are the major activation receptors, are downregulated when cultured at 1% O 2 , and cancer cell killing ability is lowered compared to NK cells grown in normal cell conditions.
- the present inventors have previously exposed NK cells to various concentrations of hypoxic conditions in vitro expansion to adapt them in a hypoxic environment, and when the NK cells are injected into the patient's body, they can maintain anticancer activity even in hypoxic conditions in cancer tissues.
- the present invention was completed by establishing culture conditions.
- Another object of the present invention is to provide a prophylactic or therapeutic use of cancer of the NK cells with improved cancer cell killing ability.
- the present invention is to culture the peripheral blood monocytes and feeder cells under cytokine for 3 to 13 days under normal oxygen conditions with an oxygen partial pressure of 20% to 22%, and then the oxygen partial pressure is increased. It provides a method for inducing and proliferating NK cells comprising the step of inducing and proliferating natural killer cells (NK cells) by further culture for 5 to 30 days in low oxygen conditions of 1% to 5%.
- NK cells natural killer cells
- the present invention also includes NK cells with improved cancer cell killing ability compared to peripheral blood mononuclear cells-derived NK cells cultured under normal oxygen conditions with an oxygen partial pressure of 20% to 22%, wherein the NK cells with improved cancer cell killing ability are in normal oxygen conditions.
- the invention also provides the use of said NK cells for the manufacture of a pharmaceutical composition for the prevention or treatment of cancer.
- the present invention also provides a method for treating cancer comprising administering to a cancer patient a pharmaceutically effective amount of the pharmaceutical composition for preventing or treating the cancer.
- NK cells induced and expanded under normal oxygen conditions in the case of NK cells induced and expanded by incubating for a certain period of time under normal oxygen conditions and further cultured under hypoxic conditions.
- cell death is reduced, aging is inhibited, cancer cell killing ability can be promoted.
- the NK cells have a long survival time and excellent cancer cell killing ability in vivo, and thus can be used as an adoptive immune cell therapy for the prevention or treatment of cancer.
- NK cells 1 is a result of confirming the effect of oxygen conditions in the induction and proliferation of NK cells from peripheral blood monocytes, peripheral blood mononuclear cells cultured for 3 weeks in normal oxygen conditions (20%) or hypoxic conditions (0.5%, 1.5%) or After culturing for 9 days in normal oxygen conditions, and further cultured in low oxygen conditions (1.5%) shows the measured cell number.
- Figure 2a is a graph comparing the proliferation of NK cells induced in normal oxygen conditions, and NK cells according to the present invention induced by further culture in hypoxic conditions after culture in normal oxygen conditions
- Figure 2b is induced in normal oxygen conditions
- Figure 2c is a graph comparing the cancer cell killing ability of NK cells induced in normal oxygen conditions and NK cells according to the present invention.
- FIG. 3 is a graph comparing the killing ability of NK cells induced in normal oxygen conditions and A375 cells, a melanoma cell line under various oxygen conditions of the NK cells according to the present invention.
- Figure 4 is a result confirming the change in the NK cells induced in normal oxygen conditions and the activating receptors and inhibitory receptors of NK cells according to the present invention.
- 5 is a result confirming the expression of p16, an aging marker in NK cells induced in normal oxygen conditions and NK cells according to the present invention.
- Figure 6 is a result confirming the cancer cell killing ability of NK cells induced in normal oxygen conditions and NK cells according to the present invention in xenograft hematological cancer model.
- the present invention is cultured peripheral blood monocytes and feeder cells under cytokines for 3 days to 13 days under normal oxygen conditions with an oxygen partial pressure of 20% to 22%, hypoxia with an oxygen partial pressure of 1% to 5%
- the present invention relates to a method of inducing and proliferating NK cells, which further comprises inducing and proliferating natural killer cells (NK cells) by further culturing for 5 to 30 days under conditions.
- NK cells natural killer cells
- the normal oxygen condition means a cell culture condition having an oxygen partial pressure of 20% to 22%
- a low oxygen condition means a cell culture condition having an oxygen partial pressure of 1% to 5%, or 1.5% to 3%.
- Induction and proliferation culture method of NK cells of the present invention is characterized in that the peripheral blood monocytes are cultured for a certain period of time under normal oxygen conditions, and further cultured under low oxygen conditions to induce and proliferate NK cells.
- peripheral blood monocytes under cytokines were cultured for 3 days to 13 days under vegetative cells and normal oxygen conditions with an oxygen partial pressure of 20% to 22%, and 5 days under hypoxic conditions with an oxygen partial pressure of 1% to 5%. It may be further incubated for 30 days.
- peripheral blood monocytes may be derived from peripheral blood of normal or cancer patients.
- the feeder cells may be irradiated Jurkat cells and irradiated EBV-LCL cells. More specifically, the feeder cells may be a mixture of irradiated Jurkat cells and irradiated EBV-LCL cells in a ratio of about 1: 1 cell number, but is not particularly limited thereto.
- peripheral blood monocytes and feeder cells may be co-cultured by mixing at a ratio of about 1: 1 cells, but are not particularly limited thereto.
- the cytokine may comprise interleukin-2 (IL-2).
- IL-2 interleukin-2
- the NK cells derived above may be cells having a CD3 - CD56 + phenotype.
- the medium used for the induction and proliferation culture of the NK cells can be used without limitation, known cell culture medium added with serum.
- the serum can be used without limitation the kind of known serum used for cell culture.
- NK cells according to the induction and proliferation culture method of the NK cells of the present invention has a larger number of cells than NK cells derived from peripheral blood monocytes cultured under normal oxygen conditions.
- NK cells when transferred to hypoxic conditions (1.5% or 0.5%) when less than 3 days of culture
- the growth rate of NK cells was significantly higher than that of the control group when the cells were transferred to hypoxic conditions after 9 days of culture under normal oxygen conditions.
- the proliferation rate was increased by about 60%
- the cell death confirmation experiment was reduced by about 50%
- the cancer cell killing ability was increased by 20% to 40% by the investigation of cancer cell killing ability.
- the cancer cell killing ability of the NK cells in the hypoxic condition was tested, compared with the NK cells cultured continuously in the normal oxygen condition, the cancer cell killing ability for solid cancer was superior, the NK cells have a high expression of CD107a (killing capacity measure) In addition, the secretion of IFN- ⁇ is increased.
- NKp44 an activation receptor and molecules related to cancer cell killing ability, perforin and granzyme B are increased.
- the expression of the aging marker p16 is reduced, it can be seen that less aging compared to NK cells continuously cultured under normal oxygen conditions.
- NK cells induced by culturing under normal oxygen conditions and further cultured under hypoxic conditions showed significantly better cancer cell killing ability than NK cells induced under normal conditions.
- NK cells of the present invention can be used as an active ingredient in the composition for the prevention or treatment of cancer, the present invention compared to NK cells derived from peripheral blood monocytes cultured in normal oxygen conditions with an oxygen partial pressure of 20% to 22% NK cells with improved cancer cell killing ability, wherein the NK cells with improved cancer cell killing ability compared to peripheral blood monocyte-derived NK cells cultured under normal oxygen conditions, CD107a, NKp44, perforin, and granzyme B It provides a pharmaceutical composition for the prevention or treatment of cancer, wherein the expression of is increased, the secretion of IFN-gamma is increased, and the expression of p16 is reduced.
- the present invention provides the use of said NK cells for the manufacture of a pharmaceutical composition for the prevention or treatment of cancer.
- the present invention provides a method for treating cancer, comprising administering to a cancer patient a pharmaceutically effective amount of the pharmaceutical composition for preventing or treating the cancer.
- the pharmaceutical composition may comprise an active ingredient or an active or inactive pharmaceutically acceptable carrier which constitutes a composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
- the cancer includes solid cancer, blood cancer, and the like, but is not particularly limited thereto.
- treatment means any action that inhibits, alleviates or beneficially alters the clinical situation associated with a disease. Treatment can also mean increased survival compared to the expected survival if untreated. Treatment includes simultaneously prophylactic measures in addition to therapeutic means.
- an "individual” may be a vertebrate, preferably a mammal, such as a dog, cat, mouse, human, or the like.
- composition of the present invention may be formulated further comprising a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier refers to a carrier or diluent that does not significantly irritate an organism and does not inhibit the biological activity and properties of the administered component.
- the pharmaceutically acceptable carrier in the present invention may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, If desired, other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added to formulate them in the form of injectables suitable for infusion into tissues or organs. It may also be formulated as an isotonic sterile solution, or as a dry preparation (particularly a lyophilized preparation), which may optionally be an injectable solution with the addition of sterile water or physiological saline.
- composition of the present invention may further include a filler, an excipient, a disintegrant, a binder and a lubricant.
- the compositions of the present invention may also be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the term "administration" refers to introducing a composition of the present invention to a patient in any suitable manner, wherein the route of administration of the composition of the present invention is via oral or parenteral various routes as long as the target tissue can be reached. May be administered. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, nasal administration, pulmonary administration, rectal administration, but is not limited thereto.
- an effective amount means an amount necessary to delay or entirely stop the onset or progression of the particular disease to be treated.
- the composition may be administered in a pharmaceutically effective amount. It will be apparent to those skilled in the art that a suitable total daily dose may be determined by the practitioner within the correct medical judgment.
- the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved and whether other agents are used in some cases, the age, weight, general state of health, sex of the patient. And various factors and similar factors well known in the medicinal art, including diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or concurrent with the specific composition.
- peripheral blood monocytes were isolated from the buff coat. Then, 10% FBS and 1% penicillin / streptomycin were added to RPMI1640 medium at a ratio of 1: 0.5: 0.5 in the presence of IL-2 500 U / ml using 100 Gy irradiated Jurkat cell line and irradiated EBV-LCL cell line The culture was co-cultured in hRPMI medium and exchanged with hRPMI medium added with 500 U / ml of IL-2 once every 2-3 days.
- Ficoll Ficoll-paqueTM PLUS, GE healthcare
- the culture was carried out for 9 days at normal oxygen conditions and then moved to 1.5% O 2 conditions for about 3 weeks. At this time, it was incubated while exchanging IL-2 with hRPMI medium added at 500 U / ml.
- peripheral blood monocytes were cultured for 3 weeks in normal oxygen conditions (20%) and hypoxic conditions (0.5% and 1.5%), or normal oxygen as described in Example 1. After culturing for 9 days under conditions (20%), the cells were moved to hypoxic conditions (1.5%), and cultured for 3 weeks, and the cell number was measured by a hematocytometer. At this time, it was incubated while exchanging IL-2 with hRPMI medium added at 500 U / ml.
- the number of cells increased under normal oxygen conditions, but the cells did not proliferate or exhibited insufficient growth effects under hypoxic conditions.
- NK cells normal oxygen conditions (20% O 2 ) and NK cells cultured after 5 days of culture under normal oxygen conditions (1.5% O 2 ) (Hypoxia) Cell proliferation was confirmed. To this end, 3 ⁇ 10 5 cells were cultured from each of the cultured cells, and then stained with Percp-labeled CD3 mAb and APC-labeled CD56mAb to confirm cell proliferation of cells that are CD3 - CD56 + .
- the cell death was confirmed by staining Annexin V and 7AAD in the experimental and control groups, respectively.
- the cells were labeled with Chromium for 1 hour, co-cultured with NK cells at a ratio of 1: 1, and after 4 hours, the supernatant was taken to a gamma counter. Isotope values were identified.
- the growth rate of NK cells was increased by about 60% when cultured in hypoxic conditions, and cell death was reduced by about 50% when cultured in hypoxic conditions.
- cancer cell killing ability was increased by 20-40% compared to cells cultured under normal oxygen conditions when cultured in hypoxic conditions.
- NK cells and target cells were mixed at a 1: 1 ratio, incubated at 37 ° C. for 1 hour, 2.5 ⁇ l of FITC labeled anti CD107a mAb, Golgi stop (BD pharmingen), and 37 for 5 hours. Incubated at °C. After incubation, Percp-labeled CD3 mAb and APC-labeled CD56mAb were added and reacted at 4 ° C. for 20 minutes.
- NK cells cultured in a hypoxic condition had high expression of CD107a (death killing scale) and increased secretion of IFN- ⁇ .
- NKp44 As shown in FIG. 4, when cultured in hypoxic conditions, NKp44, an NK cell activation receptor, and perforin and granzyme B, molecules related to cancer cell killing ability, were increased.
- NK cells cultured by moving to hypoxic conditions are less aging than NK cells cultured under normal oxygen conditions.
- PKH-labeled human T lymphoblastoid cell line CEM in 8-week-old NSG mice was injected 5 ⁇ 10 6 into the mouse abdominal cavity and 1 ⁇ 10 7 NK cells were injected in 48 hours after the cancer cells remained in the abdominal cavity. Collected and analyzed by flow cytometry.
- NK cells cultured by moving to hypoxic conditions were superior to cancer cell killing ability against blood cancer compared to NK cells cultured under normal oxygen conditions.
- the present invention can be used in the field of adoptive immune cell therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un procédé de mise en prolifération et de culture de cellules immunitaires dans des conditions hypoxiques. Lorsque les cellules NK, qui sont induites par la co-culture de cellules mononucléaires du sang périphérique et de cellules nourricières en présence de cytokines dans des conditions normoxiques, sont transférées dans des conditions hypoxiques de manière à les faire proliférer et à les cultiver, la prolifération cellulaire augmente, l'apoptose s'atténue, la capacité de destruction des cellules cancéreuses augmente, et la sénescence se réduit par comparaison avec les cellules NK cultivées en continu uniquement dans des conditions normoxiques. Ainsi, les cellules NK mises en prolifération et cultivées dans des conditions hypoxiques sont utilisables comme d'excellents agents thérapeutiques de cellules immunitaires adoptives pour la prévention ou le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0053418 | 2016-04-29 | ||
KR20160053418 | 2016-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017188790A1 true WO2017188790A1 (fr) | 2017-11-02 |
Family
ID=60160970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/004595 WO2017188790A1 (fr) | 2016-04-29 | 2017-04-28 | Procédé de mise en prolifération et de culture de cellules immunitaires dans des conditions hypoxiques |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101968184B1 (fr) |
WO (1) | WO2017188790A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018165265A1 (fr) * | 2017-03-08 | 2018-09-13 | Nantcell, Inc. | Cellules nk hypoxiques et procédés associés |
CN111757745A (zh) * | 2018-02-01 | 2020-10-09 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210207097A1 (en) | 2018-05-31 | 2021-07-08 | Korea University Research And Business Foundation | Expansion and culture of human-derived natural killer cells by using igfbp2 |
KR20230060099A (ko) | 2021-10-27 | 2023-05-04 | 고려대학교 산학협력단 | Il-23을 이용하여 종양미세환경을 극복할 수 있는 자연살해세포 증식방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140035102A (ko) * | 2012-09-13 | 2014-03-21 | (주)케이셀바이오 | 100㎖ 이하 말초혈액으로부터 nk세포의 대량 증식 방법 |
KR20150039592A (ko) * | 2012-05-07 | 2015-04-10 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010069066A (ko) | 2000-01-12 | 2001-07-23 | 이종원 | 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법 |
-
2017
- 2017-04-28 KR KR1020170055411A patent/KR101968184B1/ko active IP Right Grant
- 2017-04-28 WO PCT/KR2017/004595 patent/WO2017188790A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150039592A (ko) * | 2012-05-07 | 2015-04-10 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
KR20140035102A (ko) * | 2012-09-13 | 2014-03-21 | (주)케이셀바이오 | 100㎖ 이하 말초혈액으로부터 nk세포의 대량 증식 방법 |
Non-Patent Citations (6)
Title |
---|
BALSAMO, MIMA ET AL.: "Hypoxia Downregulates the Expression of Activating Receptors Involved m NK-cell-mediated Target Cell Killing Without Affecting ADCC", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 43, 2013, pages 2756 - 2764, XP055438446 * |
LEE, KYUNG-MI: "The Method of Expanding Immune Cell under Hypoxic Condition", IN: 2015 KUMC R&BD FAIR, 3 November 2015 (2015-11-03), Seoul, pages 63 - 71 * |
LIM, SEON AH ET AL.: "NK Cell Effector Functions are Differentially Regulated b y Hypoxic Conditions (TUM9P.1014)", THE JOURNAL OF IMMUNOLOGY, vol. 194, 1 May 2015 (2015-05-01), XP055438447 * |
LIM, SEON AH ET AL.: "NK Cell Exposed to Hypoxia During Their Ex-Vivo Expansion Acquire Higher Proliferative and Effector Function", 2015 KAI FALL CONFERENCE, 12 November 2015 (2015-11-12), Seoul, Republic of Korea, pages 28 and 108 * |
SARKAR, SUBHASHIS ET AL.: "Hypoxia Induced Impairment of NK Cell Cytotoxicity Against Multiple Myeloma can be Overcome by 1L-2 Activation of the NK Cells", PLOS ONE, vol. 8, no. 5, May 2013 (2013-05-01), pages 1 - 12, XP055438445 * |
VELASQUEZ, SONIA Y. ET AL.: "Short Term Hypoxia Synergizes with Interleukin 15 Priming in Driving Glycolytic Gene Transcription and Supports Human Natural Killer Cell Activities", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 25, 28 April 2016 (2016-04-28), pages 12960 - 12977, XP055438442 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018165265A1 (fr) * | 2017-03-08 | 2018-09-13 | Nantcell, Inc. | Cellules nk hypoxiques et procédés associés |
US11221328B2 (en) | 2017-03-08 | 2022-01-11 | Nantcell, Inc. | Hypoxic NK cells and methods therefor |
CN111757745A (zh) * | 2018-02-01 | 2020-10-09 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
EP3746095A4 (fr) * | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer |
US11066644B2 (en) | 2018-02-01 | 2021-07-20 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
CN111757745B (zh) * | 2018-02-01 | 2022-11-04 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
IL276365B1 (en) * | 2018-02-01 | 2023-06-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
Also Published As
Publication number | Publication date |
---|---|
KR20170124467A (ko) | 2017-11-10 |
KR101968184B1 (ko) | 2019-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017188790A1 (fr) | Procédé de mise en prolifération et de culture de cellules immunitaires dans des conditions hypoxiques | |
Bonanno et al. | Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures | |
US20140073050A1 (en) | Method for activation treatment of antigen-presenting cell | |
KR20150039592A (ko) | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 | |
WO2022102887A1 (fr) | Procédé de culture par prolifération massive de cellules nk | |
KR101400900B1 (ko) | 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물 | |
US11981924B2 (en) | Composition for culturing NK cells and method for culturing NK cells using same | |
Liu et al. | Intravenous transplantation of mesenchymal stromal cells has therapeutic effects in a sepsis mouse model through inhibition of septic natural killer cells | |
EP3388514B1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par des lymphocytes t régulateurs | |
Foley et al. | Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells | |
WO2022045813A1 (fr) | Composition pharmaceutique pour le traitement, la prévention ou l'inhibition des métastases d'un cancer du poumon, comprenant un exosome en tant que principe actif | |
KR101145391B1 (ko) | 말초혈액으로부터 자연 살해세포의 증식 방법 | |
WO2013168978A1 (fr) | Méthode d'induction et de prolifération de cellules tueuses naturelles dérivées de cellules mononucléaires du sang périphérique | |
WO2024090703A1 (fr) | Procédé de culture efficace pour la prolifération de cellules tueuses naturelles et son utilisation | |
Lv et al. | Functional distinction of rat liver natural killer cells from spleen natural killer cells under normal and acidic conditions in vitro | |
KR101035556B1 (ko) | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물 | |
KR101432881B1 (ko) | 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물 | |
WO2019168222A1 (fr) | Composition de milieu de culture pour la culture de lymphocytes activés anticancereux dérivées de cellules mononucléaires du sang périphérique et procédé de culture de lymphocytes activés anticancereux l'utilisant | |
WO2020231200A1 (fr) | Procédé efficace de culture de cellules tueuses naturelles, et kit à ajout de milieu associé | |
WO2020180065A1 (fr) | Procédé de préparation de cellule tueuse naturelle dans un monocyte de sang de cordon ombilical | |
WO2020153800A9 (fr) | Composition de prévention ou de traitement du cancer du sein triple négatif contenant des lymphocytes infiltrant une tumeur en tant que principe actif | |
CN108853129B (zh) | 升麻素苷在制备髓源性抑制细胞抑制药物中的应用 | |
WO2020256355A1 (fr) | Procédé d'augmentation de la teneur en cellules nk à l'aide d'un milieu de culture de cellules immunitaires d'une personne en bonne santé | |
Hu et al. | HPV16 CTL epitope peptide-activated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model | |
WO2021085853A1 (fr) | Composition pour améliorer l'activité immunitaire et procédé associé |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17789974 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17789974 Country of ref document: EP Kind code of ref document: A1 |